On Demand 2024 Saturday AM General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Opening Ceremony and Presidential Plenary
  • Atopic Dermatitis and Food Allergy Testing: Who Not to Test
  • 7 for 11: Name the Food Allergy Therapy
  • The Explosion of Secondary Immunodeficiency
  • Snooze So You Don't Lose: Sleep Medicine for the Allergist

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

Upon completion of this session, participants should be able to:

  • Explore evidence-based guidelines connecting food allergy and atopic dermatitis and identify which tests should be avoided in the patient with atopic dermatitis - with or without a consistent history of food allergy.
  • Describe inappropriate testing and how to work through positive results without consistent history and gain confidence in explaining this to other providers and patients.
  • Confront misinformation in mainstream and social media regarding food allergy and inappropriate testing. Address patient-reported complaints when expectations differ from evidence-based medicine best practices.
  • Evaluate the risks and benefits of the use of biologics in the allergy clinic. Discuss which food allergic patients should be considered for biologics and any barriers to their use. Describe the use of OIT in the food allergy clinic for different foods including multi-food OIT.
  • Examine benefits and risks of EPIT in the food-allergic patient. Illustrate the use of SLIT in food allergy, including benefits, risks and practical applications.
  • Discuss novel food allergy therapies in development. Discuss the factors that will influence patient selection and choice of therapy.
  • Indicate how hematologic malignancy and other conditions lead to clinically significant immune defects.
  • Focus on B cell depletion and other medications associated with increased risk of infection.
  • Identify an evidence-based approach between watchful waiting, vaccination, antibiotic prophylaxis, and Ig replacement.
  • Understand how asthma and allergic conditions can impact sleep quality.
  • Identify traditional, cutting edge, and Integrative Medicine techniques for sleep induction and maintenance.
  • Distinguish which patients would benefit from sleep evaluation and management and from learning the techniques highlighted by the speakers.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Part of: 
On Demand ACAAI 2024 Annual Scientific Meeting General Sessions
Rating: 
0

Gailen D. Marshall, Jr,, MD, PhD, FACAAI  
Thomas B. Casale, MD, FACAAI  
Stanley J Szefler, MD, FACAAI  
Michael E. Wechsler, MD, MMSc
Robert Sporter, MD, FACAAI  
Clinton P. Dunn, MD  
Anne Marie Singh, MD  
Matthew Greenhawt, MD, MBA, MSc, FACAAI  
David R. Stukus, MD, FACAAI
Jay A. Lieberman, MD, FACAAI  
Jonathan O'B Hourihane, MD  
Robert A. Wood, MD  
Stefania Arasi, MD, PhD, MSc  
Douglas P. Mack, MSc, MD, FRCPC  
David M. Fleischer, MD, FACAAI  
Edwin H. Kim, MD, FACAAI  
Rima A. Rachid, MD  
Aikaterini Anagnostou, MD, PhD, FACAAI
William K. Dolen, MD, FACAAI  
Sumana C. Reddy, MD  
Ivan Chinn, MD  
Sara Barmettler, MD  
S. Shahzad Mustafa, MD, FACAAI
Payel Gupta, MD, FACAAI  
Amar Dixit, MD, MBA, FACAAI  
Brian D. Robertson, MD, FACAAI  
Atoosa Kourosh, MD, MPH, FACAAI  
Peter A. Ricketti, DO, FACAAI

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Please login or create an account to take this course.